HLSC-Derived Extracellular Vesicles Attenuate Liver Fibrosis and Inflammation in a Murine Model of Non-alcoholic Steatohepatitis.


Journal

Molecular therapy : the journal of the American Society of Gene Therapy
ISSN: 1525-0024
Titre abrégé: Mol Ther
Pays: United States
ID NLM: 100890581

Informations de publication

Date de publication:
05 02 2020
Historique:
received: 12 08 2019
revised: 07 10 2019
accepted: 22 10 2019
pubmed: 24 11 2019
medline: 29 12 2020
entrez: 24 11 2019
Statut: ppublish

Résumé

Extracellular vesicles (EVs) are membrane vesicles released virtually by all cell types. Several studies have shown that stem cell-derived EVs may mimic both in vitro and in vivo the biological effects of the cells. We recently demonstrated that non-alcoholic steatohepatitis (NASH) is inhibited by treatment with human liver stem cells (HLSCs). The aim of the present study was to evaluate whether EVs released by HLSCs influence the progression of NASH, induced by a diet deprived of methionine and choline, in immunocompromised mice. EV treatment was initiated after 2 weeks of diet with a biweekly administration of three different doses. Bio-distribution evaluated by optical imaging showed a preferential accumulation in normal and, in particular, in fibrotic liver. EV treatment significantly improved liver function and reduced signs of liver fibrosis and inflammation at both morphological and molecular levels. In particular, we observed that, out of 29 fibrosis-associated genes upregulated in NASH liver, 28 were significantly downregulated by EV treatment. In conclusion, HLSC-derived EVs display anti-fibrotic and anti-inflammatory effects in a model of chronic liver disease, leading to an improvement of liver function.

Identifiants

pubmed: 31757759
pii: S1525-0016(19)30470-8
doi: 10.1016/j.ymthe.2019.10.016
pmc: PMC7001005
pii:
doi:

Substances chimiques

Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

479-489

Informations de copyright

Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.

Références

Exp Eye Res. 2001 Dec;73(6):765-80
pubmed: 11846508
Immunol Rev. 2008 Dec;226:205-18
pubmed: 19161426
Hepatology. 2016 Jul;64(1):73-84
pubmed: 26707365
Clin Liver Dis. 2009 Nov;13(4):511-31
pubmed: 19818302
Stem Cell Res Ther. 2018 Feb 06;9(1):31
pubmed: 29409540
Stem Cells Int. 2016;2016:8468549
pubmed: 27127520
Stem Cells Int. 2016;2016:1073140
pubmed: 26649044
Stem Cells Int. 2019 Jun 2;2019:6351091
pubmed: 31281379
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Stem Cells Transl Med. 2017 Apr;6(4):1262-1272
pubmed: 28213967
Cell Biol Int. 2017 May;41(5):466-475
pubmed: 28191696
Stem Cell Rev Rep. 2019 Feb;15(1):93-111
pubmed: 30191384
Sci Rep. 2019 Mar 14;9(1):4468
pubmed: 30872726
J Cell Physiol. 2018 Dec;233(12):9330-9344
pubmed: 29266258
Int J Mol Med. 2014 May;33(5):1055-63
pubmed: 24573178
J Extracell Vesicles. 2018 Apr 17;7(1):1461505
pubmed: 29696080
BMC Bioinformatics. 2013 Apr 15;14:128
pubmed: 23586463
Stem Cell Res Ther. 2014 Nov 10;5(6):124
pubmed: 25384729
Front Immunol. 2018 Jul 19;9:1639
pubmed: 30072992
Adv Drug Deliv Rev. 2016 Nov 15;106(Pt A):148-156
pubmed: 26928656
Stem Cells Int. 2018 Mar 4;2018:6079642
pubmed: 29686713
Cytotherapy. 2016 Dec;18(12):1548-1559
pubmed: 27592404
Sleep. 2015 Oct 01;38(10):1583-91
pubmed: 26085300
Mol Ther. 2017 Feb 1;25(2):465-479
pubmed: 28089078
Stem Cells. 2006 Dec;24(12):2840-50
pubmed: 16945998
Tissue Eng Part C Methods. 2010 Feb;16(1):123-32
pubmed: 19397473
Int J Mol Med. 2016 Nov;38(5):1359-1366
pubmed: 28025988
Exp Cell Res. 2014 Aug 15;326(2):230-9
pubmed: 24786317
Exp Cell Res. 2012 Feb 1;318(3):276-87
pubmed: 22108588
Front Immunol. 2018 Jun 13;9:1326
pubmed: 29951064
J Extracell Vesicles. 2016 Feb 19;5:29975
pubmed: 26901056
Stem Cell Res Ther. 2017 Jan 23;8(1):9
pubmed: 28115012
Liver Transpl. 2017 Jun;23(6):791-803
pubmed: 28407355
PLoS One. 2015 May 27;10(5):e0127991
pubmed: 26017539
Stem Cell Res Ther. 2014 Jun 10;5(3):76
pubmed: 24915963
Oncotarget. 2018 Jan 2;9(26):18594-18606
pubmed: 29719629
Stem Cells Dev. 2013 Mar 15;22(6):845-54
pubmed: 23002959
Hepatology. 2013 Jan;57(1):311-9
pubmed: 22829291
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Stem Cells Int. 2018 Dec 24;2018:3212643
pubmed: 30675167

Auteurs

Stefania Bruno (S)

Department of Medical Sciences, University of Torino, Torino, Italy; Molecular Biotechnology Centre, University of Torino, Torino, Italy.

Chiara Pasquino (C)

Department of Medical Sciences, University of Torino, Torino, Italy; Molecular Biotechnology Centre, University of Torino, Torino, Italy.

Maria Beatriz Herrera Sanchez (MB)

Molecular Biotechnology Centre, University of Torino, Torino, Italy; 2i3T Società per la Gestione dell'Incubatore di Imprese e per il Trasferimento Tecnologico Scarl, University of Torino, Torino, Italy.

Marta Tapparo (M)

Department of Medical Sciences, University of Torino, Torino, Italy; Molecular Biotechnology Centre, University of Torino, Torino, Italy.

Federico Figliolini (F)

Molecular Biotechnology Centre, University of Torino, Torino, Italy; 2i3T Società per la Gestione dell'Incubatore di Imprese e per il Trasferimento Tecnologico Scarl, University of Torino, Torino, Italy.

Cristina Grange (C)

Department of Medical Sciences, University of Torino, Torino, Italy; Molecular Biotechnology Centre, University of Torino, Torino, Italy.

Giulia Chiabotto (G)

Department of Medical Sciences, University of Torino, Torino, Italy.

Massimo Cedrino (M)

Molecular Biotechnology Centre, University of Torino, Torino, Italy.

Maria Chiara Deregibus (MC)

2i3T Società per la Gestione dell'Incubatore di Imprese e per il Trasferimento Tecnologico Scarl, University of Torino, Torino, Italy.

Ciro Tetta (C)

Unicyte Srl, Torino, Italy.

Giovanni Camussi (G)

Department of Medical Sciences, University of Torino, Torino, Italy; Molecular Biotechnology Centre, University of Torino, Torino, Italy. Electronic address: giovanni.camussi@unito.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH